Associated tags: Therapy, Patient, Alopecia areata, Itolizumab, Health, Biotechnology, Clinical Trials, Research, Pharmaceutical industry, Pharmaceutical, Science, Oncology, Safety, Trial of the century, Degenerative disease
Locations: NEW YORK, PENNSYLVANIA, PHILADELPHIA, CANADA, ONO, MASSACHUSETTS, PA, ONTARIO, QUEBEC, III, WALL STREET, HAIR, UNITED STATES, NORTH AMERICA, CALIFORNIA, NY
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Partnership,
Therapy,
Ono Pharmaceutical,
Marriott Marquis,
Conference Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.
Key Points:
- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.
- Management will provide an overview of the company’s clinical programs – including EQ101 for the treatment for alopecia areata with data expected before the end of June 2024 – the company’s partnership with Ono Pharmaceutical, and 2024 milestones.
- Management will also be available for one-on-one meetings during the conference.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Itolizumab,
Therapy,
JPY,
Pharmaceutical industry Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD).
Key Points:
- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD).
- Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-month option exercise period to acquire Equillium’s rights to itolizumab.
- “Our clinical development team has done an excellent job of recruiting and activating trial sites globally,” said Bruce Steel, chief executive officer at Equillium.
- Equillium is also eligible to receive up to $101.4 million upon the achievement of certain development, regulatory, and commercialization milestones.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Investment,
Lupus nephritis,
Alopecia areata,
Partnership,
Trial of the century,
Exercise,
Therapy,
Patient,
Chemistry,
CMC,
Itolizumab,
Inc.,
G&A,
Pharmaceutical industry Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
Key Points:
- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
- Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023.
- Research and development (R&D) expenses for the first quarter of 2024 were $9.7 million, compared to $9.3 million for the same period in 2023.
- General and administrative expenses for the first quarter of 2024 remained relatively constant compared to the same period in 2023.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
DSM-IV codes,
Gene expression,
Itolizumab,
ALCAM,
CD6,
VLA4,
HUVEC,
Vaccine Reduction of CD6 on T cells or blocking of ALCAM on the human umbilical vein endothelial cells (HUVEC), prevents the adhesion of Effector T cells to the endothelial monolayer.
Key Points:
- Reduction of CD6 on T cells or blocking of ALCAM on the human umbilical vein endothelial cells (HUVEC), prevents the adhesion of Effector T cells to the endothelial monolayer.
- Itolizumab treatment significantly reduced the trans-endothelial migration of pathogenic T cells, with high correlation of effector T cells’ migration index with the CD6 levels on the cell surface.
- This suggests a direct role of the CD6-ALCAM pathway and indirect T cell mobility regulation through downregulation of VLA4.
- The poster presentation is available on the Presentations page of Equillium’s website under the “Itolizumab MOA” tab.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.
Key Points:
- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.
- The Compensation Committee approved the stock option as an inducement material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock option has an exercise price per share equal to $2.11, Equillium’s closing stock price on April 1, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Equillium through the applicable vesting dates.
- The stock option is subject to the terms and conditions of Equillium’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant.
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
Clinical Trials,
EOS,
Itolizumab,
Week,
S1P,
Dialysis,
Type,
AMP,
Exercise,
Ono Pharmaceutical,
Infection,
Lymphocytopenia,
Patient,
Serum albumin,
Peripheral edema,
CD6,
Lupus,
EULAR,
EGFR,
Therapy,
Proteinuria,
ALC,
Lupus nephritis,
Nursing Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients.
Key Points:
- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients.
- Key topline data from the Type B portion of the EQUALISE study in lupus nephritis:
Subjects were highly proteinuric: baseline mean UPCR of 4.9 g/g.
- Itolizumab treatment (over 6 months) was also associated with reductions in absolute lymphocyte counts (ALC), another known pharmacodynamic effect.
- Two subjects had at least one serious adverse event, none of which were related to study treatment.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Itolizumab,
Organic acid,
Harvard Medical School,
Exercise,
Alopecia areata,
ASN,
Partnership,
Patient,
Gastrointestinal tract,
ACR,
IL-9,
Acquisition,
G&A,
MPA,
Dermatology,
Investment,
MPH,
Therapy,
Eosinophilic esophagitis,
Retirement,
Inflammatory bowel disease,
Lupus nephritis,
JAK,
Pharmaceutical industry Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
Key Points:
- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
- Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period in 2022.
- General and administrative (G&A) expenses for the fourth quarter of 2023 were $3.2 million, compared with $5.2 million for the same period in 2022.
- Net cash used in operating activities in the fourth quarter was $5.7 million.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Partnership,
Therapy,
Conference,
Ono Pharmaceutical Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.
Key Points:
- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.
- Management will provide an overview of the company’s clinical programs, partnership with Ono Pharmaceutical and 2024 milestones, during both conferences.
- Webcast access will be available on the “Events & Presentations” page under the Investor Relations tab on the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.... .
- The presentation at the LD Micro conference will be live-streamed on the event website at https://ldinv14.sequireevents.com/ .
Retrieved on:
Wednesday, March 27, 2024
NEW YORK, March 27, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, EQ, M, GOOGL, and PSX.
Key Points:
- NEW YORK, March 27, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, EQ, M, GOOGL, and PSX.
- Click a link below then choose between in-depth options trade idea report or a stock score report.
- Options Report – Ideal trade ideas on up to seven different options trading strategies.
- The report shows all vital aspects of each option trade idea for each stock.
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
